Keywords: نسبت هزینه-بهره وری افزایشی; Multiple sclerosis; Pharmaceutical reimbursement, Decision-making; CHMP; committee for medicinal for human use; ICER; incremental cost-effectiveness ratio; MCID; minimal clinically important difference; MS; multiple sclerosis; PBAC; pharmaceutical benefit
مقالات ISI نسبت هزینه-بهره وری افزایشی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: نسبت هزینه-بهره وری افزایشی; AUC; area under the curve; CE; cost effectiveness; CEAC; cost-effectiveness acceptability curve; CI; confidence interval; DMSIC; Drug and Medical Supply Information Center; DRG; diagnosis-related group; DSA; deterministic sensitivity analysis; EGFR; epide
Keywords: نسبت هزینه-بهره وری افزایشی; CI; confidence interval; CMDVI; comparative modeling of dengue vaccine impact; DALY; disability-adjusted life year; GBD; global burden of disease; ICER; incremental cost-effectiveness ratio; WHO; World Health Organization;
Keywords: نسبت هزینه-بهره وری افزایشی; Bibliotherapy; Cognitive behaviour therapy; Cost effectiveness; Health anxiety; Illness anxiety disorder; Internet therapy; Somatic symptom disorder; BIB-CBT; cognitive behavioural bibliotherapy; EQ-5D; EuroQol 5D; G-ICBT; therapist-guided internet cognit
Keywords: نسبت هزینه-بهره وری افزایشی; Influenza; Cost-effectiveness; Vaccination; Trivalent; Quadrivalent; Dynamic transmission model; GDP; gross domestic product; ICER; incremental cost-effectiveness ratio; HIV; human immunodeficiency virus; IBS; individual based simulation; I$; internationa
Keywords: نسبت هزینه-بهره وری افزایشی; Helicobacter pylori; Neoplasm; Precancer; Preneoplasia; AG; atrophic gastritis; CRC; colorectal cancer; EGD; esophagogastroduodenoscopy; ESD; endoscopic submucosal dissection; GA; gastric adenocarcinoma; ICER; incremental cost-effectiveness ratio; IM; int
Keywords: نسبت هزینه-بهره وری افزایشی; ICER; incremental cost-effectiveness ratio; LAMS; lumen-apposing metal stent; LOS; length of stay; PS; plastic stent; PCD; percutaneous drainage; WON; walled-off necrosis; WTP; willingness to pay;
Keywords: نسبت هزینه-بهره وری افزایشی; Advanced Liver Disease; Mortality; Portal Hypertension; Comparison; DRG; diagnosis-related group; HCUP; Healthcare Cost and Utilization Project; HE; hepatic encephalopathy; ICER; incremental cost-effectiveness ratio; LVP+A; serial large volume paracentesi
Keywords: نسبت هزینه-بهره وری افزایشی; AAA; abdominal aortic aneurism; CTC; colonography; CS; colonoscopy; CRC; colorectal cancer; CEA; cost-effective analysis; CER; cost-effectiveness ratios; FAP; familial polyposis; FOBT; faecal-occult-blood tests; GDP; gross-domestic product; HNPCC; heredit
Keywords: نسبت هزینه-بهره وری افزایشی; Pressure ulcers; Oral nutritional support; Healing; Cost-effectiveness; Incremental cost-effectiveness ratio;
Keywords: نسبت هزینه-بهره وری افزایشی; Obsessive-compulsive disorder; Deep brain stimulation; Economic evaluation; Psychiatry; CBT; cognitive behavioral therapy; ICER; incremental cost-effectiveness ratio; IPG; implantable pulse generator; OCD; obsessive-compulsive disorder; QALY; Quality adju
Keywords: نسبت هزینه-بهره وری افزایشی; ARIAS; automated diabetic retinopathy image assessment system; CE; Conformité Européenne; CI; confidence interval; DR; diabetic retinopathy; ICER; incremental cost-effectiveness ratio; M0; no maculopathy; M1; maculopathy; NHS DESP; National Health Servi
Keywords: نسبت هزینه-بهره وری افزایشی; CAD; coronary artery disease; CCTA; coronary computed tomographic angiography; ECHO; echocardiogram; ETT; exercise treadmill testing; ICA; invasive coronary angiography; ICER; incremental cost-effectiveness ratio; MPS; myocardial perfusion scintigraphy; S
Keywords: نسبت هزینه-بهره وری افزایشی; Pneumococcal conjugate vaccine; Cost-effectiveness; Mongolia; Vaccine; Budget impact; PCV13; AMC; advance market commitment; AOM; acute otitis media; CFR; case-fatality risk; DALY; disability-adjusted life year; GDP; gross domestic product; GNI; gross nat
Keywords: نسبت هزینه-بهره وری افزایشی; CT; computed tomography; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; EQ-5D; EuroQol five-dimension questionnaire; EYLL; expected years of life lost; GDP; gross domestic product; ICER; incremental cost-effectiveness ratio; NCKUH
Keywords: نسبت هزینه-بهره وری افزایشی; Peanut oral immunotherapy; Cost-effectiveness analysis; FAQL-PF; Food Allergy Quality of Life-Parent Form; ICER; Incremental cost-effectiveness ratio; OIT; Oral immunotherapy; POIT; Peanut oral immunotherapy; QALY; Quality-adjusted life-year; QOL; Quality
Keywords: نسبت هزینه-بهره وری افزایشی; CAD; computer-aided-detection; DCIS; ductal carcinoma in situ; FNAC; fine-needle aspiration cytology; ICER; incremental cost-effectiveness ratio; NHS-EED; Economic Evaluation Database produced by the NIHR Centre for Reviews and Dissemination (CRD) at the
Keywords: نسبت هزینه-بهره وری افزایشی; CAN$; Canadian dollars; CXL; collagen cross-linking; DALK; deep anterior lamellar keratoplasty; ICER; incremental cost-effectiveness ratio; PKP; penetrating keratoplasty; QALY; quality-adjusted life year;
Keywords: نسبت هزینه-بهره وری افزایشی; Cost Effectiveness; Budget Impact; Public Health; Health Care Expenses; CEA; cost-effectiveness analysis; CHEERS; The Consolidated Health Economic Evaluation Reporting Standards; DAA; direct-acting antiviral; HCV; hepatitis C virus; ICER; incremental cost
Keywords: نسبت هزینه-بهره وری افزایشی; Diabetes; Obesity; Low-carbohydrate diet; Shared medical appointments; Comparative effectiveness; Health services research; BMI; body mass index; BP; blood pressure; CDE; certified diabetes educator; DMC; Data Monitoring Committee; EHR; electronic health
Keywords: نسبت هزینه-بهره وری افزایشی; EE; economic evaluation; OECD; Organization for Economic Co-operation and Development; CEA; cost-effectiveness analysis; CER; cost-effectiveness ratio; ICER; incremental cost-effectiveness ratio; WTP; willingness to pay; NICE; National Institute for Healt
Keywords: نسبت هزینه-بهره وری افزایشی; ACER; average cost-effectiveness ratio; CT; computerized tomography; ICER; incremental cost-effectiveness ratio; LDCT; low dose computerized tomography; LYs; life years; NLST; national lung screening trial; QALYs; quality adjusted life years; Lung cancer;
Keywords: نسبت هزینه-بهره وری افزایشی; Hip replacement; THR; THA; Dual mobility; Bearings; Dislocation; Instability; Incremental cost-effectiveness ratio; Cost-effectiveness; Markov model; Economic analysis
Keywords: نسبت هزینه-بهره وری افزایشی; EQ-5D; EuroQol-5 Dimension; ICER; incremental cost-effectiveness ratio; QALY; quality-adjusted life year; QOL; quality of life; SF-36; Short-Form 36; VM; venous malformation;
Keywords: نسبت هزینه-بهره وری افزایشی; urology; venous thrombosis; pulmonary embolism; cost-benefit analysis; prevention & control; ACCP; American College of Chest Physicians; ASCO; American Society of Clinical Oncology; DVT; deep vein thrombosis; EDP; extended duration prophylaxis; ICER; incr
Keywords: نسبت هزینه-بهره وری افزایشی; Medico-economic evaluation; Oncology; Survival; Progression-free survival; Incremental cost-effectiveness ratio; French Drug Authority (Haute Autorité de santé [HAS]); NICE; IQWIG;
Keywords: نسبت هزینه-بهره وری افزایشی; Pap; Papanicolaou; HR; high-risk; HPV; human papillomavirus; LR; low risk; PHU; public health unit; MOHLTC; Ontario Ministry of Health and Long-Term Care; QALY; quality-adjusted life years; HSIL; high-grade cervical squamous intraepithelial lesion; CIN; c
Keywords: نسبت هزینه-بهره وری افزایشی; Cost-utility analysis; Costs; Economics; Rehabilitation; Spinal cord decompression; Spinal cord injury; Spine surgery; Timing; Trauma; Utility; AIS; American Spinal Injury Association Impairment Scale; ICER; Incremental cost-effectiveness ratio; OMHLTC; O
Keywords: نسبت هزینه-بهره وری افزایشی; ICER; incremental cost-effectiveness ratio; QALY; quality-adjusted life-year; ITC; indirect treatment comparison; Chronic lymphocytic leukaemia; Obinutuzumab; Chlorambucil; Rituximab; Ofatumumab; Cost-effectiveness; Costs;
Keywords: نسبت هزینه-بهره وری افزایشی; DME; diabetic macular edema; DR; diabetic retinopathy; FP; family physician; ICER; incremental cost-effectiveness ratio; NPDR; nonproliferative diabetic retinopathy; PDR; proliferative diabetic retinopathy; QALY; quality-adjusted life-year; SiDRP; Singapo
Keywords: نسبت هزینه-بهره وری افزایشی; AIPT; advanced interventional pain therapy; CRPS; complex regional pain syndrome; DPN; diabetic peripheral neuropathy; DRG; dorsal root ganglion; FBSS; failed back surgery syndrome; FDA; Food and Drug Administration; IDDS; intrathecal drug delivery system
Keywords: نسبت هزینه-بهره وری افزایشی; MNP; microneedle patch; QALY; quality-adjusted life years; ICER; incremental cost-effectiveness ratio; SEIR; susceptible-exposed-infectious-recovered; BTC; behind-the-counter; WTP; willingness-to-pay; Microneedle patch; Influenza; Influenza vaccination; E
Keywords: نسبت هزینه-بهره وری افزایشی; CABG; cost effectiveness; PCI; quality of life; stent(s); ASCERT; American College of Cardiology Foundation and the Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies; CABG; coronary artery bypass g
Keywords: نسبت هزینه-بهره وری افزایشی; Economic evaluation; Modeling; QALY; Intractable epilepsy; Ketogenic diet; Vagus nerve stimulation; KD; ketogenic diet; VNS; vague nerve stimulation; CAU; care as usual; QALY; quality adjusted life years; ICER; incremental cost-effectiveness ratio; CEAC;
Keywords: نسبت هزینه-بهره وری افزایشی; ICER; PPI; Antibody; Screening; CD; celiac disease; CPT; Current Procedural Terminology; DGP; deamidated gliadin peptide antibodies; EGD; esophagogastroduodenoscopy; EMA; endomysial antibodies; GERD; gastroesophageal reflux disease; GFD; gluten-free diet;
Keywords: نسبت هزینه-بهره وری افزایشی; CT-FNA; computed tomography-guided fine-needle aspiration; FDG-PET; 18F-fluoro-deoxyglucose positron emission tomography; ICER; incremental cost-effectiveness ratio; NB; navigation bronchoscopy; QALYs; quality-adjusted life years; VATS; video-assisted tho
Keywords: نسبت هزینه-بهره وری افزایشی; AEFI; Adverse events following immunization; CCC; Complex chronic condition; CFR; Case fatality ratio; hSBA; Human serum bactericidal assay; ICER; Incremental cost-effectiveness ratio; IMD; Invasive meningococcal disease; IMPACT; Immunization Monitoring P
Keywords: نسبت هزینه-بهره وری افزایشی; budget impact analysis; cost-effectiveness; fecal incontinence; incontinence-free days; incremental cost-effectiveness ratio; InterStim; NASHA/Dx; sacral nerve stimulation; Solesta; quality-adjusted life-years;
Keywords: نسبت هزینه-بهره وری افزایشی; AF; Atrial fibrillation; OAC; Oral anticoagulant; INR; International normalised ratio; TTR; Time in therapeutic range; NOAC; Novel oral anticoagulant; ARISTOTLE; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AVER
Keywords: نسبت هزینه-بهره وری افزایشی; DALYs; disability-adjusted life-years; DPT3; final dose of diphtheria, pertussis, and tetanus vaccination; EMR; Eastern Mediterranean region; GAVI; Global Alliance for Vaccines and Immunization; GDP; gross domestic product; ICER; incremental cost-effectiv
Keywords: نسبت هزینه-بهره وری افزایشی; CVG; cost per vaccinated girl; GDP; gross domestic product; HPV; human papillomavirus; ICER; incremental cost-effectiveness ratio; LMIC; low or middle income country; QALY; quality adjusted life year; WHO; World Health Organization; Human papillomavirus;
Keywords: نسبت هزینه-بهره وری افزایشی; cost-effectiveness analysis; cost-utility analysis; HTA; incremental cost-effectiveness ratio; incremental cost-utility ratio; Poland
Cost effectiveness of transcatheter aortic valve implantation in patients with aortic stenosis in Japan
Keywords: نسبت هزینه-بهره وری افزایشی; Transcatheter aortic valve implantation; Incremental cost-effectiveness ratio; Cost-effectiveness; Quality-adjusted life year; Aortic stenosis;
The cost-effectiveness of the arthroscopic Bankart versus open Latarjet in the treatment of primary shoulder instability
Keywords: نسبت هزینه-بهره وری افزایشی; Level II; Economic Analysis; Shoulder instability; Markov; Latarjet; Bankart; cost-effectiveness; incremental cost-effectiveness ratio;
Cost-Effectiveness of Self-Expandable Transcatheter Aortic Valves in Intermediate-Risk Patients
Keywords: نسبت هزینه-بهره وری افزایشی; ACC; American College of Cardiology; AHA; American Heart Association; CAD; Canadian dollar; CADTH; Canadian Agency for Drugs and Technologies in Health; EQ-5D; EuroQoL; ICER; incremental cost-effectiveness ratio; ICU; intensive care unit; LOS; length of s
Chuna manual therapy combined with acupuncture and cupping for frozen shoulder (adhesive capsulitis): Study protocol for a multicenter, randomized, patient-assessor blind, clinical trial
Keywords: نسبت هزینه-بهره وری افزایشی; FS; frozen shoulder; ROM; range of motion; NSAIDs; non-steroidal anti-inflammatory drugs; CMT; chuna manual therapy; CONSORT; consolidated standards of reporting trials; SPIRIT; standard protocol items: recommendations for interventional trials; KMD; Kore
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States
Keywords: نسبت هزینه-بهره وری افزایشی; Vaccine; Vaccination; Herpes zoster; Public health impact; Cost-effectiveness; ACIP; Advisory Committee on Immunization Practices; AEs; adverse events; DSA; deterministic sensitivity analysis; HZ; shingles, Herpes zoster; RZV; Adjuvanted Recombinant Zoste
Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study
Keywords: نسبت هزینه-بهره وری افزایشی; CISNET; Cancer Intervention and Surveillance Modelling Network; CTFPHC; Canadian Task Force on Preventive Health Care; DRG; diagnosis related group; ICER; incremental cost-effectiveness ratio; LDCT; low-dose computed tomography; LYG; life-years gained; MI
Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies
Keywords: نسبت هزینه-بهره وری افزایشی; ASCO; American Society of Clinical Oncology; BRAF; B-raf proto-oncogene, serine/threonine kinase; CTLA4; cytotoxic T-lymphocyte associated protein 4; ESMO; European Society for Medical Oncology; FDA; Food and Drug Administration; ICER; incremental cost-ef
Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals
Keywords: نسبت هزینه-بهره وری افزایشی; Simulation Model; Sofosbuvir; Health Economics; DAA; oral direct-acting antiviral; HCV; hepatitis C virus; ICER; incremental cost-effectiveness ratio; LT; liver transplantation; MELD; Model for End-stage Liver Disease; QALY; quality-adjusted life year; SV